Amgen (AMGN) Plans Quarterly Dividend of $0.47
Amgen (NASDAQ:AMGN) declared a quarterly dividend on Wednesday, March 6th. Stockholders of record on Thursday, May 16th will be given a dividend of $0.47 per share on Friday, June 7th. This represents a $1.88 dividend on an annualized basis and a yield of 2.02%.
Several analysts have also recently commented on the stock. Analysts at S&P Equity Research raised their price target on shares of Amgen from $100.00 to $104.00 in a research note to investors on Tuesday, February 26th. They now have a “buy” rating on the stock. On a related note, analysts at Guggenheim raised their price target on shares of Amgen from $93.00 to $95.00 in a research note to investors on Tuesday, February 26th. They now have a “neutral” rating on the stock. Finally, analysts at Bank of America raised their price target on shares of Amgen to $99.00 in a research note to investors on Monday, February 25th.
Eleven analysts have rated the stock with a buy rating, three have assigned an overweight rating, and sixteen have given a hold rating to the stock. The stock currently has an average rating of “overweight” and an average price target of $96.98.
Amgen (AMGN) traded down 0.18% on Wednesday, hitting $93.27. Amgen (AMGN) has a 52-week low of $65.37 and a 52-week high of $93.76. The stock’s 50-day moving average is currently $86.22. The company has a market cap of $70.512 billion and a price-to-earnings ratio of 16.93.
Amgen last released its earnings data on Wednesday, January 23rd. The company reported $1.40 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.42 by $0.02. The company had revenue of $4.42 billion for the quarter, compared to the consensus estimate of $4.37 billion. During the same quarter in the prior year, the company posted $1.21 earnings per share. The company’s quarterly revenue was up 11.3% on a year-over-year basis. Amgen has set its FY13 guidance at $6.85-7.15 EPS. Analysts expect that Amgen (AMGN) will post $7.19 EPS for the current fiscal year.
Amgen Inc. (Amgen) is a biotechnology medicines company. The Company discovers, develops, manufactures and markets medicines for illnesses.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.